Literature DB >> 18494053

Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model.

Feng Xie1, Nan Luo, Hin-Peng Lee.   

Abstract

AIM: To compare the costs and effectiveness of no screening and no eradication therapy, the population-based Helicobacter pylori (H pylori) serology screening with eradication therapy and (13)C-Urea breath test (UBT) with eradication therapy.
METHODS: A Markov model simulation was carried out in all 237900 Chinese males with age between 35 and 44 from the perspective of the public healthcare provider in Singapore. The main outcome measures were the costs, number of gastric cancer cases prevented, life years saved, and quality-adjusted life years (QALYs) gained from screening age to death. The uncertainty surrounding the cost-effectiveness ratio was addressed by one-way sensitivity analyses.
RESULTS: Compared to no screening, the incremental cost-effectiveness ratio (ICER) was $16166 per life year saved or $13571 per QALY gained for the serology screening, and $38792 per life year saved and $32525 per QALY gained for the UBT. The ICER was $477079 per life year saved or $390337 per QALY gained for the UBT compared to the serology screening. The cost-effectiveness of serology screening over the UBT was robust to most parameters in the model.
CONCLUSION: The population-based serology screening for H pylori was more cost-effective than the UBT in prevention of gastric cancer in Singapore Chinese males.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18494053      PMCID: PMC2712169          DOI: 10.3748/wjg.14.3021

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication.

Authors:  S Danese; A Armuzzi; A Romano; F Cremonini; M Candelli; F Franceschi; V Ojetti; A Venuti; P Pola; G Gasbarrini; A Gasbarrini
Journal:  Hepatogastroenterology       Date:  2001 Mar-Apr

2.  Endoscopic screening for gastric cancer.

Authors:  Yock Young Dan; J B Y So; Khay Guan Yeoh
Journal:  Clin Gastroenterol Hepatol       Date:  2006-06       Impact factor: 11.382

Review 3.  Gastric cancer epidemiology and risk factors.

Authors:  Jon R Kelley; John M Duggan
Journal:  J Clin Epidemiol       Date:  2003-01       Impact factor: 6.437

4.  Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.

Authors:  Kuo-Ching Yang; Gen-Ming Wang; Jui-Hao Chen; Tong-Jong Chen; Shui-Cheng Lee
Journal:  J Formos Med Assoc       Date:  2003-12       Impact factor: 3.282

5.  Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation.

Authors:  P Roderick; R Davies; J Raftery; D Crabbe; R Pearce; P Patel; P Bhandari
Journal:  J Med Screen       Date:  2003       Impact factor: 2.136

6.  Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.

Authors:  Benjamin Chun-Yu Wong; Shiu Kum Lam; Wai Man Wong; Jian Shun Chen; Ting Ting Zheng; Rui E Feng; Kam Chuen Lai; Wayne Hsing Cheng Hu; Siu Tsan Yuen; Suet Yi Leung; Daniel Yee Tak Fong; Joanna Ho; Chi Kong Ching; Jun Shi Chen
Journal:  JAMA       Date:  2004-01-14       Impact factor: 56.272

7.  Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.

Authors:  C Gambaro; C Bilardi; P Dulbecco; E Iiritano; P Zentilin; C Mansia; P Usai; S Vigneri; V Savarino
Journal:  Dig Liver Dis       Date:  2003-11       Impact factor: 4.088

8.  [Cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: Markov decision analysis].

Authors:  Qian Wang; Pi-huan Jin; Guo-wei Lin; San-rong Xu; Jie Chen
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2003-02

9.  Comparison of 5- and 10-year survival rates in operated gastric cancer patients. Assessment of the 5-year survival rate as a valid indicator of postoperative curability.

Authors:  S Koga; N Kaibara; H Kishimoto; H Nishidoi; O Kimura; T Okamoto; H Tamura
Journal:  Langenbecks Arch Chir       Date:  1982

10.  Survival of patients with stomach cancer in Changle city of China.

Authors:  Jun Tian; Xiao-Dong Wang; Zhen-Chun Chen
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

View more
  12 in total

1.  Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus.

Authors:  Antonio Rollan; Juan Pablo Arab; M Constanza Camargo; Roberto Candia; Paul Harris; Catterina Ferreccio; Charles S Rabkin; Juan Cristóbal Gana; Pablo Cortés; Rolando Herrero; Luisa Durán; Apolinaria García; Claudio Toledo; Alberto Espino; Nicole Lustig; Alberto Sarfatis; Catalina Figueroa; Javier Torres; Arnoldo Riquelme
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 2.  Helicobacter pylori in First Nations and recent immigrant populations in Canada.

Authors:  Nicola Jones; Naoki Chiba; Carlo Fallone; Alan Thompson; Richard Hunt; Kevan Jacobson; Karen Goodman
Journal:  Can J Gastroenterol       Date:  2012-02       Impact factor: 3.522

3.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Virchows Arch       Date:  2011-12-22       Impact factor: 4.064

4.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Endoscopy       Date:  2011-12-23       Impact factor: 10.093

Review 5.  Subtotal gastrectomy for gastric cancer.

Authors:  Roberto Santoro; Giuseppe Maria Ettorre; Eugenio Santoro
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

Review 6.  Helicobacter pylori associated gastric intestinal metaplasia: Treatment and surveillance.

Authors:  Kevin Sze-Hang Liu; Irene Oi-Ling Wong; Wai K Leung
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 7.  Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention.

Authors:  Iris Lansdorp-Vogelaar; Linda Sharp
Journal:  Best Pract Res Clin Gastroenterol       Date:  2013-09-27       Impact factor: 3.043

8.  The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention.

Authors:  Yi-Chia Lee; Tony Hsiu-Hsi Chen; Han-Mo Chiu; Chia-Tung Shun; Hung Chiang; Tzeng-Ying Liu; Ming-Shiang Wu; Jaw-Town Lin
Journal:  Gut       Date:  2012-06-14       Impact factor: 23.059

9.  Cost-effectiveness of Helicobacter pylori screening followed by eradication treatment for employees in Japan.

Authors:  A Kowada
Journal:  Epidemiol Infect       Date:  2018-07-30       Impact factor: 4.434

Review 10.  Non-invasive diagnostic tests for Helicobacter pylori infection.

Authors:  Lawrence Mj Best; Yemisi Takwoingi; Sulman Siddique; Abiram Selladurai; Akash Gandhi; Benjamin Low; Mohammad Yaghoobi; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.